End-Stage Renal Disease

End-Stage Renal Disease
https://www.scientificanimations.com/ · CC BY-SA 4.0 · source
Name	End-Stage Renal Disease
Caption	Dialysis machine and vascular access
Icd10	N18.6
Specialty	Nephrology

End-Stage Renal Disease is the terminal phase of chronic kidney failure in which kidneys permanently lose function necessitating renal replacement therapy such as dialysis or transplantation. It has major implications for public health systems in countries like the United States, United Kingdom, Canada, and Australia and is addressed by organizations such as the World Health Organization, Centers for Disease Control and Prevention, National Health Service (England), and Kidney Disease: Improving Global Outcomes. Clinical care involves multidisciplinary teams including nephrologists trained at institutions like Mayo Clinic, Cleveland Clinic, and Johns Hopkins Hospital and relies on technologies developed by companies such as Fresenius Medical Care and DaVita Inc..

Terminology and Classification

The term denotes irreversible kidney failure corresponding to the advanced stage of chronic kidney disease first codified in classifications by bodies including KDIGO and the National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative. International Classification of Diseases coding (eg ICD-10) records this condition under codes used in administrative datasets maintained by agencies such as the World Health Organization and country-level health ministries like the Department of Health and Human Services (United States). Clinical guidelines from organizations like the American Society of Nephrology and the European Renal Association–European Dialysis and Transplant Association standardize staging, terminology, and thresholds for initiating renal replacement as informed by trials conducted at centers including Harvard Medical School and Stanford University School of Medicine.

Epidemiology and Risk Factors

Prevalence and incidence data are tracked by registries such as the United States Renal Data System, the European Renal Association Registry, and national programs in Japan, Germany, and France. Major risk factors include longstanding diabetes mellitus treated in settings like Joslin Diabetes Center, chronic hypertension with management protocols developed by organizations such as the American Heart Association, glomerulonephritides monitored by pathology services at Mayo Clinic, and genetic disorders including polycystic kidney disease studied at centers like University of California, San Francisco. Socioeconomic determinants reflected in datasets from institutions such as the World Bank and health inequities examined by The Lancet also influence incidence across regions including Sub-Saharan Africa, South Asia, and Latin America.

Pathophysiology and Clinical Presentation

Progression to irreversible renal failure results from nephron loss due to mechanisms described in textbooks from publishers such as Oxford University Press and research articles in journals like The New England Journal of Medicine and Journal of the American Medical Association. Common etiologies include diabetic nephropathy with foundational research from Joslin Diabetes Center, hypertensive nephrosclerosis described in cohorts at Johns Hopkins Hospital, chronic glomerulonephritis studied at Massachusetts General Hospital, and obstructive uropathy treated in centers such as Mayo Clinic. Typical clinical features are uremia requiring evaluation in emergency departments affiliated with universities like Yale School of Medicine and include fatigue, edema, electrolyte disturbances notable in literature from Karolinska Institutet, and complications such as anemia and mineral bone disorder discussed in guidelines by International Society of Nephrology.

Diagnosis and Staging

Diagnosis relies on laboratory criteria and imaging endorsed by societies including KDIGO and the American College of Radiology. Staging uses estimated glomerular filtration rate formulas validated in cohorts from institutions like University of Leicester and involves measurement modalities described in publications from Imperial College London and Johns Hopkins University. Confirmatory testing includes urine analysis, renal ultrasound protocols developed by the Radiological Society of North America, and biopsy pathology standards maintained by centers such as Cleveland Clinic. National screening recommendations from agencies including the Centers for Disease Control and Prevention and Public Health England influence diagnostic pathways.

Management and Treatment

Renal replacement options include hemodialysis performed in centers operated by organizations like Fresenius Medical Care and DaVita Inc., peritoneal dialysis techniques promoted by programs at University of Toronto, and kidney transplantation coordinated through networks such as UNOS and transplant centers like Massachusetts General Hospital and Mayo Clinic. Conservative management pathways are described in European guidelines from the European Renal Association–European Dialysis and Transplant Association and palliative care frameworks developed by institutions including St Christopher's Hospice. Pharmacological strategies draw on evidence synthesized by groups such as the Cochrane Collaboration and include agents for anemia management approved by regulators like the Food and Drug Administration and European Medicines Agency. Vascular access procedures are performed by surgeons trained in programs at Johns Hopkins Hospital and Stanford University School of Medicine.

Complications and Prognosis

Complications encompass cardiovascular disease with risk profiles characterized in studies at Framingham Heart Study and arrhythmia risk explored by researchers at Mayo Clinic, infections tracked by public health agencies including the CDC, and metabolic bone disease reviewed by the International Osteoporosis Foundation. Prognosis depends on comorbidity burden and access to care, with survival and quality-of-life outcomes reported by registries such as the United States Renal Data System and cohort studies published in journals like The Lancet. Policy responses and funding mechanisms from bodies including the Centers for Medicare & Medicaid Services and national ministries of health shape access to transplantation waiting lists managed by UNOS and dialysis services provided by international healthcare systems.

Category:Kidney diseases